GLP-1s may reduce alcohol use disorder
Lilly is pursuing brenepatide in Phase 3 trials specifically for alcohol use disorder, after observational data showed GLP-1 users spontaneously drink less.
Snapshot · The Prof G Pod with Scott Galloway
Why People Are Losing Faith in Healthcare
Explore episode
Jun 4, 2026
Where this was said
Beyond Obesity: Inflammation, Addiction, and Cancer
At 14:30 · chapter starts 10:10
What began as a diabetes drug keeps revealing new capabilities. Ricks walks through the cascade: inflammation reduction (GLP-1s appear to be powerful anti-inflammatories, relevant to arthritis, asthma, psoriasis), and then the stranger, harder-to-explain behavioral effects. Patients in trials spontaneously drank less alcohol, gambled less, and shopped less online — without being asked or prompted. The mechanism, Ricks theorizes, is that alcohol is chemically close to glucose, and the same brain signaling that reduces sugar cravings quiets alcohol desire too. Critically, he pushes back on the 'joy kill switch' narrative: people don't lose pleasure, they just find less appetite for excess. Lilly is now running Phase 3 trials on brenepatide for alcohol use disorder. On pain: retatrutide, the triple-acting drug expected to launch next year, showed the most powerful knee pain reduction ever recorded pharmacologically — a finding with enormous implications given the scale of chronic pain in America. Cancer connections remain observational but are striking: people on GLP-1s for 5–6 years appear to have lower rates of colorectal and breast cancer.
Retatrutide: The Most Powerful Pain Drug Ever Tested
Lilly's triple-acting GLP-1 drug retatrutide, expected for launch next year, produced the most powerful pharmacological pain reduction ever recorded for knee arthritis. The finding was unexpected and points to GLP-1s as potential game-changers for America's massive chronic pain burden.
GLP-1s cut knee pain more than any drug ever
Lilly's triple-acting retatrutide demonstrated the most powerful pain-reduction ever recorded pharmacologically for knee arthritis in clinical studies.
Obesity linked to 200+ chronic diseases
Obesity is described as a 'nodal health condition' connected to more than 200 chronic diseases, making GLP-1 treatment uniquely high-leverage.
GLP-1s Reduce Addiction to Alcohol, Gambling, and Online Shopping
Patients in GLP-1 trials spontaneously reduced alcohol intake, gambling, and even online shopping without being prompted. Lilly is now pursuing a Phase 3 drug — brenepatide — specifically for alcohol use disorder, as the mechanism appears to quiet hedonic urges broadly.
LillyDirect and the Regressive Healthcare Pricing System
US drug pricing is systemically regressive: the largest institutional buyers get the lowest prices, while uninsured or underinsured individuals pay the most. Lilly created LillyDirect to let consumers buy directly at institutional prices, cutting Zepbound's cost by 60% to $399/month.
Similar snapshots
500 self-help techniques → 12 levers
Spencer Greenberg and Jeremy Stevenson analyzed almost 500 self-improvement techniques and found they all reduce to just 12 underlying psychological drivers.
Cold exposure: weak long-term evidence
Cold exposure has good short-term alertness benefits but the evidence base for long-term health benefits is much weaker than popularly believed.
20 habit techniques tested; almost none worked
In a randomized study of 20 habit-formation techniques run on hundreds of people, almost none of the techniques produced statistically meaningful results.
Tiny habit users stick to the FULL habit more
People given a tiny-habit fallback option (e.g. 10 squats instead of gym) were actually MORE successful at completing the full habit, not less.
Habit reflection = standout technique
The most effective habit-formation technique was 'habit reflection' — recalling a past successful habit, writing down what helped, then applying those lessons to a new habit.
Behavioral activation rivals CBT for depression
A study found that simply scheduling enjoyable activities was as effective as standard cognitive behavioral therapy for depression, leading to its own therapy called behavioral activation.
Worry time: batch all worries to 5 PM
The 'worry time' technique — deferring all worries to a designated time of day — helps people realize they have more control over worry than they thought and reveals it is less useful than it feels.
Sleeping faster by trying to stay awake
A study found that participants told to try to stay awake while in bed fell asleep faster than participants told to try to sleep — illustrating the paradox of direct effort.
Social anxiety eliminated in ~6 months
Spencer Greenberg reduced his severe social anxiety dramatically in roughly 6 months through a structured exposure therapy hierarchy, culminating in asking strangers for hugs.
